Patents by Inventor Paul F. Cavanaugh, Jr.

Paul F. Cavanaugh, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
    Patent number: 5626838
    Abstract: The present invention provides novel methods for prevention or treatment of primary and recurring squamous cell carcinoma of the oral cavity or oropharynx comprising topical administration, to the oral cavity or oropharynx, of an effective amount of an NSAID, especially a composition administering from about 0.001% to about 0.2% ketorolac to the oral cavity, alone or as an adjunct to surgery and/or radiation therapy.
    Type: Grant
    Filed: March 13, 1995
    Date of Patent: May 6, 1997
    Assignee: The Procter & Gamble Company
    Inventor: Paul F. Cavanaugh, Jr.
  • Nuclease resistant compounds
    Patent number: 5567810
    Abstract: Compounds, compositions and methods for inhibiting gene expression are disclosed. The compounds comprise oligonucleotide sequences of from about 9 to about 200 bases having a diol at either or both termini. Preferred diols are polyalkyleneglycols, preferably polyethyleneglycols. Pharmaceutical compositions comprising the compounds and a physiologically acceptable carrier and methods of inhibiting gene expression in mammals comprising administering such compounds are also provided. Methods for inhibiting nuclease cleavage of compounds are also provided.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: October 22, 1996
    Assignee: Sterling Drug, Inc.
    Inventors: Alexander L. Weis, Fred T. Oakes, Frederick H. Hausheer, Paul F. Cavanaugh, Jr., Patricia S. Moskwa
  • Exonuclease resistant terminally substituted oligonucleotides
    Patent number: 5245022
    Abstract: Compounds, compositions and methods for inhibiting gene expression are disclosed. The compounds comprise oligonucleotide sequences of from about 9 to about 200 bases having a diol at either or both termini. Preferred diols are polyalkyleneglycols, preferably polyethyleneglycols. Pharmaceutical compositions comprising the compounds and a physiologically acceptable carrier and methods of inhibiting gene expression in mammals comprising administering such compounds are also provided. Methods for inhibiting nuclease cleavage of compounds are also provided.
    Type: Grant
    Filed: August 3, 1990
    Date of Patent: September 14, 1993
    Assignee: Sterling Drug, Inc.
    Inventors: Alexander L. Weis, Fred T. Oakes, Frederick H. Hausheer, Paul F. Cavanaugh, Jr., Patricia S. Moskwa